Dr. Alan Blum and Cancer Network have partnered to assemble a four-part slideshow series addressing the history of America’s smoking pandemic. Part 3 highlights a period of regulation and legislation against the tobacco industry, and litigation in the form of class action and state lawsuits.
Practice & Policy
The American Society of Clinical Oncology released a statement calling for the rapid expansion of use of the human papillomavirus (HPV) vaccine to help protect thousands of people from HPV-associated cancers.
While continuing to warn against use of laparoscopic power morcellators for the removal of uterus or uterine fibroids in most women, the FDA is allowing the marketing of a containment system for use with certain power morcellators to isolate tissue not suspected to be cancerous.
An ASCO expert panel has endorsed a Cancer Care Ontario guideline on the role of patient and disease factors in the selection of adjuvant therapy for women with early-stage breast cancer.
A pilot program that integrated costs associated with some of the most common cancer treatment protocols with electronic medical records was successful in providing value to both physicians and patients.
ASCO updated guidelines, recommending that higher-risk premenopausal ER-positive breast cancer patients receive ovarian suppression with adjuvant endocrine therapy.
A panel of experts at the ASCO have reviewed and endorsed Cancer Care Ontario’s guideline on Active Surveillance for the Management of Localized Prostate Cancer.
The 2012 change in guidelines regarding PSA testing for prostate cancer had a different effect on testing rates depending on which physician specialty was doing the testing.
ASCO has published a guideline on biomarker use to guide decisions for adjuvant systemic treatment for women with early-stage, invasive breast cancer.
In this Q&A we examine Right-to-Try drug laws and discuss tips for clinicians with terminally ill patients who have exhausted all their therapy options.